How to outsmart NK cell tolerance

OncoImmunology

Volumn 4, Issue 9, 2015, Pages 1-3

  Terszowski, Grzegorz ^a   Klein, Christian ^b   Schmied, Laurent ^a   Stern, Martin ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Roche Innovation Center Zurich   (Switzerland)

Author keywords

ADCC; CD20; HLA; KIR; Lirilumab; NK cell tolerance; Obinutuzumab; Rituximab

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; LIRILUMAB; OBINUTUZUMAB; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER INHIBITION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MULTIPLE MYELOMA; NATURAL KILLER CELL; PROGRESSION FREE SURVIVAL; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR IMMUNITY;

EID: 84944449642     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1016708     Document Type: Article

References (10)

1. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner GJ. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 2011; 118:3347-9; PMID:21768303; http://dx. doi.org/10.1182/blood-2011-05-351411
2. Terszowski G, Klein C, Stern M. KIR/HLA interactions negatively affect rituximab-but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. J Immunol 2014; 192:5618-24; PMID:24795454; http:// dx.doi.org/10.4049/jimmunol.1400288
3. Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou L, Hsu K, Czuczman MS, Cheson B, Kaplan L, et al. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2014; 2:878-89; PMID:24958280; http://dx.doi.org/10.1158/2326-6066.CIR-13-0158
4. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; PMID:11806974; http://dx. doi.org/10.1182/blood.V99.3.754
5. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-402; PMID:20194898; http://dx.doi.org/ 10.1182/blood-2009-06-225979
6. Liu SD, Chalouni C, Young JC, Junttila TT, Sliwkowski MX, Lowe JB. Afucosylated antibodies increase activation of FcgammaRIIIa-dependent signaling components to intensify processes promoting ADCC. Cancer Immunol Res 2015; 3:173-83
7. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370:1101-10; PMID:24401022; http:// dx.doi.org/10.1056/NEJMoa1313984
8. Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr, Blaser BW, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009; 114:2667-77; PMID:19553639; http://dx.doi.org/10.1182/blood-2009-02-206532
9. Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, Etienne A, Andre P, Romagne F, Benson D, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012; 120:4317-23; PMID:23002117; http:// dx.doi.org/10.1182/blood-2012-06-437558
10. Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous C, Czerwinski D, Rajapaksa A, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014; 123:678-86; PMID:24326534; http://dx.doi.org/10.1182/blood-2013-08-519199